{Reference Type}: Journal Article
{Title}: Cabazitaxel's ototoxicity: An animal study and histopathologic research.
{Author}: Bucak A;Özdemir Ç;Kınar A;Ulu Ş;Kuzu S;Günebakan Ç;Kahveci OK;
{Journal}: J Cancer Res Ther
{Volume}: 19
{Issue}: 0
{Year}: 2023 Apr
{Factor}: 1.331
{DOI}: 10.4103/jcrt.jcrt_774_21
{Abstract}: <B>UNASSIGNED: </B>Chemotherapeutic agents can have both serious side effects and ototoxicity, which can be caused by direct toxic effects or by metabolic derangement by the agents. Cabazitaxel (CBZ) is a next-generation semi-synthetic taxane derivative that is effective in both preclinical models of human tumors that are sensitive or resistant to chemotherapy and in patients suffering from progressive prostate cancer despite docetaxel treatment. The primary aim of this study is to investigate the ototoxicity of CBZ in a rat model.<BR><B>UNASSIGNED: </B>: A total of 24 adult male Wistar-Albino rats were equally and randomly divided into four groups. CBZ (Jevtana, Sanofi-Aventis USA) was intraperitoneally administered to Groups 2, 3, and 4 at doses of 0.5, 1.0, and 1.5 mg/kg/week, respectively, for 4 consecutive weeks; Group 1 received only i.p. saline at the same time. At the end of the study, the animals were sacrificed and their cochlea removed for histopathological examination.<BR><B>UNASSIGNED: </B>: Intraperitoneal administration of CBZ exerted an ototoxic effect on rats, and the histopathological results became worse in a dose-dependent manner (P < 0.05).<BR><B>UNASSIGNED: </B>: Our findings suggest that CBZ may be an ototoxic agent and can damage the cochlea. More clinical studies should be conducted to understand its ototoxicity.